
iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. (ITOS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ITOS · as of Jun 8, 2026
Key Statistics
Explore iTeos Therapeutics, Inc. Data
itos stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 37.5%
The ITOS analyst consensus is Hold, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $18.20, representing +79.31% upside from the current price of $10.15.
Competitors & Peers
itos competitorsStock Performance
Full HistoryAbout iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes …
what is iteos therapeutics, inc. · itos stock overview · iteos therapeutics, inc. company profile · who is iteos therapeutics, inc. ceo · itos NASDAQ · iteos therapeutics, inc. headquarters · iteos therapeutics, inc. business segments
About Stock Overview & Key Data
iTeos Therapeutics, Inc. (ITOS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 24, 2020. As of the latest trading session, ITOS stock price is $10.15, with a market capitalization of $448.7M. The stock has returned -0.59% over the past 12 months and +28.48% year-to-date.
According to 8 Wall Street analysts, the consensus rating for iTeos Therapeutics, Inc. stock is Hold, with an average 12-month price target of $18.20. In fiscal year 2024, iTeos Therapeutics, Inc. reported revenue of $35.0M and net income of -$134.4M. For detailed data — including iTeos Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, iTeos Therapeutics, Inc. (ITOS) stock price is $10.15. The stock is traded on NASDAQ under the ticker symbol ITOS. The 52-week range is $4.80 – $17.63.